Topical retinoid
Pregnancy: Avoid — though systemic absorption is minimal, all retinoids are class-teratogenic. Use azelaic acid or topical erythromycin in pregnancy.
Adapalene
Brand names: Differin, Epiduo (with benzoyl peroxide)
Adult dose
Dose: Apply a thin layer to affected area once daily at night
Route: Topical
Frequency: Once daily (evening)
Wash skin and pat dry before application. Avoid eyes, lips, mucous membranes, broken skin.
Clinical pearls
- First-line topical retinoid for mild–moderate acne (NICE NG198) — better tolerated than tretinoin or isotretinoin gel.
- Effects take 8–12 weeks — counsel about realistic timelines and initial flare.
- Combination Epiduo (adapalene + benzoyl peroxide) addresses comedones and inflammation simultaneously — preferred over monotherapy in NICE NG198.
- Pea-sized amount for whole face is sufficient — over-application increases irritation without benefit.
- Continue maintenance therapy 2–3 nights/week long-term to prevent relapse after clearance.
Contraindications
- Pregnancy (relative — minimal systemic absorption but retinoid class teratogenicity)
- Severe eczema or seborrhoeic dermatitis on the same area
- Hypersensitivity to adapalene or excipients
- Children under 12 (limited data)
Side effects
- Erythema, dryness, scaling — peaks at 2–4 weeks
- Burning, stinging on application
- Photosensitivity
- Initial 'purge' / acne flare in first 2–4 weeks (counsel patient — do not stop)
- Hypopigmentation / hyperpigmentation in dark skin (rare)
Interactions
- Other irritants (benzoyl peroxide unless combined product, salicylic acid, glycolic acid): apply at different times of day
- Sun exposure: increased photosensitivity — recommend daily SPF
Monitoring
- Treatment response at 8–12 weeks
Reference: BNF 90; SmPC Differin / Epiduo; NICE NG198 (Acne vulgaris 2021); BAD Acne Guideline. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD